medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2018, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2018; 34 (4)

Histocompatibility of haploindénticos donor for hematopoietic progenitor cells transplantation

Bencomo HAA, Yavi AMG, Chang MA, Morera BLM, Ustáriz GCR

Language: Spanish
References: 26
Page: 41-52
PDF size: 137.29 Kb.


ABSTRACT

Introduction: The transplant is an alternative to achieve the healing of patients with haemopathies. The reduction in the number of siblings worldwide has increased the need to address haploidentical HLA transplantation.
Objective: To characterize the compatibility at the level of antigens and HLA epitopes to receptors and donors for the haploidentical transplantation of hematopoietic progenitors.
Methods: 215 recipients, 95 female and 120 male and 313 siblings were studied. Mothers were also studied in 95 cases and parents of 73 recipients.
Results: In the B locus the highest number of class I incompatibilities was observed. In class II, DRB1 was significantly superior to DQ. The lowest number of incompatible eplets was observed between the recipients with the father and the incompatibilities less than 10 eplets were more frequent with the mother. When considering the compatibility of eplets in loci B and DRB1, more than 45% of haploidentical donors are epitopes compatible with the receptor. In 34 recipients of 215 (15.8%), donors were identified with total compatibility of HLA class epitopes. I, II or both. These results should be considered for the preparation of an algorithm for the selection of donors in haploidentical transplantation.
Conclusions: Among the Cuban recipients of haploidentical transplantation of hematopoietic progenitors and their possible donors can be found couples with high compatibility at the level of antigens and epitopes of the HLA system, so this characterization could be included in the selection algorithms.


REFERENCES

  1. Mahdi BM. A glow of HLA typing in organ transplantation. ClinTransl Med. 2013;2(1):6.

  2. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010 Apr;75(4):291-455.

  3. Abbas AK, Lichtman AH, Pillai S. Major Histocompatibility Complex Molecules and Antigen Presentation to T Lymphocytes. Cellular and molecular immunology. 7th ed. Philadelphia: Elsevier/Saunders; 2010. p. 109-38.

  4. Erlich H. HLA DNA typing: past, present, and future. Tissue Antigens. 2012 Jul;80(1):1-11.

  5. Kelley J, Walter L, Trowsdale J. Comparative genomics of major histocompatibility complexes. Immunogenetics. 2005 Jan;56(10):683-95.

  6. Parslow TG, Stites DP, Terr A, Imboden J. Presentación de antígenos y complejo principal de histocompatibilidad. Inmunología básica y clínica. 10 ed. México D.F: El manual moderno; 2007 p. 93-108.

  7. Bencomo-Hernández A. A propósito del primer año del Centro de Ingeniería Celular y Trasplante de Órganos y Tejidos (CICEL). Rev Cubana Hematol Inmunol Hemoter.2014; 30(3): 192-5.

  8. Duquesnoy RJ. Antibody-reactive epitope determination with HLA Matchmaker and its clinical applications. Tissue Antigens 2011; 77, 525-34.

  9. Silva E, Alba A, Castro A, Carrascal M, Buckel E, Aguiló J. Evaluation of HLA Matchmaker Compatibility as Predictor of Graft Survival and Presence of Anti-HLA Antibodies. Transplant Proceed. 2010, 42; 266-9

  10. Sapir-Pichhadze R, Tinckam K, Quach K, Logan AG, Laupacis A, John R, et al. HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested casecontrol study. Am J Transplant. 2015; 15:137-48.

  11. Duquesnoy RJ, Witvliet M, Doxiadis II, de Fijter H, Claas FH. HLA Matchmakerbased strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates. Transplant Int. 2004; 17:22-30.ric hematopoietic stem cell transplant recipients: using an affordable in-house qPCR assay for management of HCMV infection under limited resources.Transpl Int. 2015 May;28(5):594-603.

  12. Sypek MP, Alexander SI, Cantwell L, Ierino FL, Ferrari P, Walker AM, et al. Optimizing Outcomes in Pediatric Renal Transplantation Through the Australian Paired Kidney Exchange Program. Am J Transplant . 2017; 17:534-41.

  13. Marsh SG. Nomenclature for factors of the HLA system, update June 2016. Int J Immunogenet. 2016 Oct;43(5):320-9. doi: 10.1111/iji.12284

  14. World Medical Association (AMM). Helsinki Declaration. Ethical principles for medical research involving human subjects. Assist Inferm Ric. 2001 Apr- Jun;20(2):104-7.

  15. WMA. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 2011 [updated 2011 2008 Oct; cited 2011 Jan 15]; Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf .

  16. Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J, et al. Haploidentical hematopoietic stem cell transplantation: A global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant. 2016; 22(1):23-6.

  17. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identicalsibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956-62.

  18. McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015;125(19):3024-31.

  19. Kollman C, Spellman S, Zhang M. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016; 127:260-67.

  20. Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, et al. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica. 2016;101(10): 1267-74.

  21. Morera Barrios LM, Chang Monteagudo A, García García MA, de la Guardia Peña OM, Ustariz García CR, Marcell Rodríguez L, et al. Frecuencia de genes HLA en pacientes con insuficiencia renal crónica, del occidente y centro de Cuba. Rev Cubana HematolInmunolHemoter [Internet]. 2014 [citado 2018 Sep 30];31(1):[aprox. 0 p.]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/257 .

  22. Wiebe C, Pochinco D, Blydt-Hansen TD, Ho J, Birk PE, Karpinski M, et al. Class II HLA epitope matching-A strategy to minimize de novo donors pecific antibody development and improve outcomes. Am J Transpl. 2013; 13:3114-22.

  23. Heidt S, Haasnoot GW, van Rood JJ, Witvliet MD, Claas FHJ. Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients. Kidney Int. 2018; 93:491-500.

  24. Wang Y, Zhaoa XY, Xu LP, Zhanga XH, HanaW, Chen H, et al. Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. Oncoimmunol. 2016; 5(12):e1242546.

  25. Molitor ML, Haynes LD, Jankowska-Gan E, Mulder A, Burlingham WJ. HLA class I noninherited maternal antigens in cord blood and breast milk. Hum Immunol. 2004;65(3):231-239.

  26. Tambur AR. HLA-epitope matching or eplet risk stratification: the devil is in the details. Front Immunol. 2018; 9:02010.




2020     |     www.medigraphic.com